New and Emerging Treatments and Treatment Guidelines in the Optimal Management of Moderate-to-Severe Psoriasis
Although there are multiple agents approved for the treatment of psoriasis, many patients still do not achieve optimal outcomes demonstrated by clear or almost clear skin. In addition, many patients are dissatisfied with their current treatment for psoriasis. In this CME Outfitters Snack, expert faculty provide insights and recommendations about current and emerging psoriasis treatments and management of comorbidities.
This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date: Wednesday, May 16, 2018
|Mark G. Lebwohl, MD
Sol and Clara Kest Professor and Chair
The Kimberly and Eric J. Waldman Professor
Chairman of The Kimberly and Eric J. Waldman
Department of Dermatology
Icahn School of Medicine
Mount Sinai Medical Center
New York, NY
Psoriasis is an inflammatory, autoimmune disorder with predominately joint and skin symptoms characterized by scaling and erythematous plaques that may be painful or severely pruritic, and may cause significant quality of life issues. Affecting 2% to 3% of the general population, psoriasis is linked to other serious conditions such as cardiovascular disease, psoriatic arthritis, and depression.
Although there are multiple agents approved for the treatment of psoriasis, many patients still do not achieve optimal outcomes demonstrated by clear or almost clear skin. In addition, many patients are dissatisfied with their current treatment for psoriasis.
In this CME Outfitters Snack, expert faculty provide insights and recommendations about current and emerging psoriasis treatments and management of comorbidities.
Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185.
At the end of this CE activity, participants should be able to:
- Describe the role in practice for new and emerging agents for the treatment of moderate-to-severe psoriasis.
- Develop a strategy that follows recommended guidelines for treating and managing patients with moderate-to-severe psoriasis.
Supported by Novartis Pharmaceuticals Corporation.
Physicians, pharmacists and other health care professionals managing patients with psoriasis.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs) Universal Activity Number:
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Lebwohl reports that he is an employee of the Mount Sinai Medical Center which receives research funds from AbbVie Inc.; Amgen Inc.; Anacor Pharmaceuticals, Inc.; Boehringer Ingleheim; Celgene Corporation; Eli Lilly and Company; Janssen Research & Development, LLC; Kadmon Holdings, Inc.; Medimmune/Astra Zeneca; Novartis; Pfizer Inc.; and Vidac.
Erica Perilstein, MD (peer reviewer) has nothing to disclose.
Daniela V. DiBiase, MS (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to Disclose
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.